Trial · NCT06677710
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
NCT06677710, Phase 1, Suspended, Indapta Therapeutics, INC.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis. Trials, record NCT06677710. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06677710
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
- NCT number
- NCT06677710
- Status
- Suspended
- Phases
- Phase 1
- Enrollment
- 34 participants, estimated
- Lead sponsor
- Indapta Therapeutics, INC.
- Conditions
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
- Interventions
- IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
- First posted
- 2024-11-07
- Last updated
- 2025-04-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of AEs and SAEs - (Part 1) | 1 year | Escalation Period |
| Primary | Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with IL-2 and Ocrelizumab (Part 1) | up to 21 days | Escalation Period |
| Primary | Change in cellular response of autoreactive immune cells to antigen (Part 2) | 2 years | Expansion Period |
| Secondary | Change in cellular response of autoreactive immune cells to antigen (Part 1) | 2 year | Escalation Period |
| Secondary | Incidence of AEs and SAEs - (Part 2) | 2 years | Expansion Period |
| Secondary | PK (PK; maximum drug concentration) of IDP-023 - (Part 1/2) | 2 years | Escalation and Expansion periods |
| Secondary | PK (area under the concentration-time curve) of IDP-023 - (Part 1/2) | 2 years | Escalation and Expansion periods |
| Secondary | PK (concentration reached by the drug immediately before the next dose is administered) of IDP-023 - (Part 1/2) | 2 years | Escalation and Expansion periods |
| Secondary | Time to onset of sustained disability progression over the treatment period, defined as an increase in Expanded Disability Status Scale (EDSS) - (Part 1/2) | 2 years | Escalation and Expansion periods |
| Secondary | Biologic activity of IDP-023 in the CSF over the treatment period - (Part 1/2) over the treatment period, defined as an increase in EDSS - (Part 1/2) | 2 years | Escalation and Expansion periods |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06677710
GET https://conductscience.org/api/trials/v1/NCT06677710/registered